Drug Profile
Research programme: cell therapies - Astellas Institute for Regenerative Medicine
Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Ocata Therapeutics
- Developer Astellas Institute for Regenerative Medicine
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders
- Research Corneal disorders; Glaucoma; Optic nerve disorders; Retinitis pigmentosa
Most Recent Events
- 24 Aug 2023 Preclinical development in Autoimmune-disorders is ongoing in USA (Parenteral) (Astellas Institute for Regenerative Medicine website; August 2023)
- 24 Aug 2023 Research development in Corneal-disorders is ongoing in USA (Parenteral).(Astellas Institute for Regenerative Medicine website; August 2023)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)